CStone's sugemalimab added to ESMO lung cancer guideline

CStone Pharmaceuticals (HKEX: 2616) announced that its key product, sugemalimab (Cejemly®), has been included in the European Society for Medical Oncology (ESMO) Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline. The ESMO Guideline recommends sugemalimab as a first-line combination therapy for both squamous and non-squamous NSCLC, noting substantial clinical benefits. For squamous NSCLC patients, sugemalimab-platinum-doublet chemotherapy is recommended as a Level [I, A] therapy, with an ESMO-MCBS v1.1 score of 4. Similar benefits are noted for non-squamous NSCLC. The recommendations are backed by Phase III GEMSTONE-302 trial data demonstrating significant improvements in progression-free and overall survival. Sugemalimab is already approved in China, the EU, and the UK for advanced NSCLC treatment.